Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition

Published:2023-02-28 Issue:6 Volume:62 Page:1114-1123
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Toure Mohammed A.¹²³^ORCID,Koehler Angela N.¹²³^ORCID

Affiliation:

1. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

2. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

3. The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

Funder

Division of Chemistry

Alfred P. Sloan Foundation

Center for Precision Cancer Medicine, Massachusetts Institute of Technology

Ludwig Center, Massachusetts Institute of Technology

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.biochem.2c00609

Reference86 articles.

1. Cancer Genome Landscapes

2. The emerging clinical relevance of genomics in cancer medicine

3. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

4. Transcription factors as targets for cancer therapy

5. Transcriptional Addiction in Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

2. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer;Journal of Medicinal Chemistry;2024-06-17

3. Targeting super-enhancer activity for colorectal cancer therapy;American Journal of Translational Research;2024

4. Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors;Cancers;2023-12-24

5. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers;Journal of Medicinal Chemistry;2023-11-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3